Drug shortages homepage

Welcome to Drug Shortages Canada, the website for reporting drug shortages and discontinuations in Canada. The Food and Drug Regulations require drug sellers to report when they are not able to meet demand for a product or when they stop selling a product. Information about the website and the regulations can be found on the About & Resources Page.

A shortage means, in respect of a drug, a situation in which the manufacturer to whom a document was issued under subsection C.01.014.2(1) that sets out the drug identification number assigned for the drug is unable to meet the demand for the drug.

A discontinuation means, in respect of a drug, a situation in which the manufacturer to whom a document was issued under subsection C.01.014.2(1) that sets out the drug identification number assigned for the drug, permanently ceases the sale of the drug.

Tier 3 drug shortages are those that have the greatest potential impact on Canada's drug supply and health care system. Impact is based on low availability of alternative supplies, ingredients or therapies. The Tier Assignment Committee (TAC), composed of federal and provincial/territorial governments, healthcare professionals, and industry stakeholders, makes recommendations on the tier assignment of drug shortages. The TAC assessment includes:

  • a review of the information gathered on the shortage issue, and
  • a thorough discussion on its potential impact and next steps.

Below are the newest and most recently updated Shortage and Discontinuation reports. Alternatively, please visit the Tier 3 page to see current Tier 3 Drug Shortages and associated shortage or discontinuation reports.

Drug pills

LEGEND

!!T3 denotes an actual Tier 3 shortage/discontinuation

!T3 denotes an anticipated Tier 3 shortage/discontinuation

Shortage Reports

Brand name Company Name Status Strength Update Date Updated View Report
ELIGARD TOLMAR INTERNATIONAL LTD. Actual shortage 7.5MG Updated Report 2022-01-24 152360
CALCIUM GLUCONATE INJECTION, USP 10% FRESENIUS KABI CANADA LTD Anticipated shortage 100MG Updated Report 2022-01-24 153459
CALCIUM GLUCONATE INJECTION, USP 10% FRESENIUS KABI CANADA LTD Actual shortage 100MG Updated Report 2022-01-24 147629
CALCIUM GLUCONATE INJECTION, USP 10% FRESENIUS KABI CANADA LTD Actual shortage 100MG Updated Report 2022-01-24 147622
FLUMAZENIL INJECTION FRESENIUS KABI CANADA LTD Actual shortage 0.1MG Updated Report 2022-01-24 148857
HYZAAR ORGANON CANADA INC. Anticipated shortage 12.5MG 50MG Updated Report 2022-01-24 152441
LORAZEPAM INJECTION USP PFIZER CANADA ULC Actual shortage 4MG Updated Report 2022-01-24 127901
APO-METFORMIN ER APOTEX INC Resolved 1000MG Updated Report 2022-01-24 150839
APO-FLUCONAZOLE APOTEX INC Resolved 100MG Updated Report 2022-01-24 149160
APO-DESVENLAFAXINE APOTEX INC Resolved 50MG Updated Report 2022-01-24 152301

Discontinuation Reports

Brand name Company Name Status Strength Update Date Updated View Report
CLINIMIX BAXTER CORPORATION To be discontinued 200MG 300MG 290MG 240MG 210MG 90MG 1.04G 575MG 340MG 250MG 515MG 20MG 16.6G 365MG 280MG 290MG Updated Report 2022-01-21 118612
CLINIMIX BAXTER CORPORATION To be discontinued 240MG 210MG 90MG 1.04G 575MG 340MG 250MG 515MG 20MG 10G 365MG 280MG 290MG 200MG 300MG 290MG Updated Report 2022-01-21 118601
CLINIMIX E BAXTER CORPORATION To be discontinued 205MG 261MG 58.5MG 24MG 16.6G 365MG 280MG 290MG 200MG 300MG 290MG 240MG 210MG 90MG 1.04G 575MG 340MG 250MG 515MG 20MG Updated Report 2022-01-21 118607
CHLORAX AA PHARMA INC Discontinued 2.5MG 5MG Updated Report 2022-01-21 153244
CIPRO XL BAYER INC To be discontinued 1000MG New Report 2022-01-20 153201